Logo image of REPL

REPLIMUNE GROUP INC (REPL) Stock Fundamental Analysis

USA - NASDAQ:REPL - US76029N1063 - Common Stock

5.73 USD
-0.28 (-4.66%)
Last: 9/12/2025, 8:13:25 PM
5.75 USD
+0.02 (+0.35%)
After Hours: 9/12/2025, 8:13:25 PM
Fundamental Rating

2

REPL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. REPL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. REPL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year REPL has reported negative net income.
REPL had a negative operating cash flow in the past year.
REPL had negative earnings in each of the past 5 years.
In the past 5 years REPL always reported negative operating cash flow.
REPL Yearly Net Income VS EBIT VS OCF VS FCFREPL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

REPL has a Return On Assets (-59.68%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -83.22%, REPL is in line with its industry, outperforming 51.39% of the companies in the same industry.
Industry RankSector Rank
ROA -59.68%
ROE -83.22%
ROIC N/A
ROA(3y)-38.68%
ROA(5y)-31.31%
ROE(3y)-49.49%
ROE(5y)-38.68%
ROIC(3y)N/A
ROIC(5y)N/A
REPL Yearly ROA, ROE, ROICREPL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

REPL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REPL Yearly Profit, Operating, Gross MarginsREPL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, REPL has more shares outstanding
The number of shares outstanding for REPL has been increased compared to 5 years ago.
The debt/assets ratio for REPL has been reduced compared to a year ago.
REPL Yearly Shares OutstandingREPL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
REPL Yearly Total Debt VS Total AssetsREPL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

REPL has an Altman-Z score of -2.13. This is a bad value and indicates that REPL is not financially healthy and even has some risk of bankruptcy.
REPL has a Altman-Z score (-2.13) which is in line with its industry peers.
REPL has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.21, REPL is doing worse than 68.39% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z -2.13
ROIC/WACCN/A
WACCN/A
REPL Yearly LT Debt VS Equity VS FCFREPL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

A Current Ratio of 6.94 indicates that REPL has no problem at all paying its short term obligations.
REPL has a better Current ratio (6.94) than 68.76% of its industry peers.
A Quick Ratio of 6.94 indicates that REPL has no problem at all paying its short term obligations.
REPL has a Quick ratio of 6.94. This is in the better half of the industry: REPL outperforms 69.13% of its industry peers.
Industry RankSector Rank
Current Ratio 6.94
Quick Ratio 6.94
REPL Yearly Current Assets VS Current LiabilitesREPL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

REPL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.92%.
EPS 1Y (TTM)0.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.49% on average over the next years. This is quite good.
Based on estimates for the next years, REPL will show a very strong growth in Revenue. The Revenue will grow by 136.60% on average per year.
EPS Next Y-10.21%
EPS Next 2Y14.69%
EPS Next 3Y14.83%
EPS Next 5Y13.49%
Revenue Next Year300%
Revenue Next 2Y350.89%
Revenue Next 3Y232.68%
Revenue Next 5Y136.6%

3.3 Evolution

REPL Yearly Revenue VS EstimatesREPL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
REPL Yearly EPS VS EstimatesREPL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for REPL. In the last year negative earnings were reported.
Also next year REPL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REPL Price Earnings VS Forward Price EarningsREPL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REPL Per share dataREPL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as REPL's earnings are expected to grow with 14.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.69%
EPS Next 3Y14.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for REPL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REPLIMUNE GROUP INC

NASDAQ:REPL (9/12/2025, 8:13:25 PM)

After market: 5.75 +0.02 (+0.35%)

5.73

-0.28 (-4.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners106.63%
Inst Owner Change-14.02%
Ins Owners2.02%
Ins Owner Change0.84%
Market Cap447.28M
Analysts72
Price Target7.29 (27.23%)
Short Float %25.35%
Short Ratio1.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.09%
Min EPS beat(2)-15.38%
Max EPS beat(2)-6.81%
EPS beat(4)1
Avg EPS beat(4)-6.04%
Min EPS beat(4)-15.38%
Max EPS beat(4)12.93%
EPS beat(8)3
Avg EPS beat(8)0.01%
EPS beat(12)6
Avg EPS beat(12)1.38%
EPS beat(16)7
Avg EPS beat(16)-0.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.85%
PT rev (3m)-66.89%
EPS NQ rev (1m)-16.28%
EPS NQ rev (3m)-9.44%
EPS NY rev (1m)-8.96%
EPS NY rev (3m)-14.84%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-62.48%
Revenue NY rev (3m)-68.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-2.92
FCFYN/A
OCF(TTM)-2.82
OCFYN/A
SpS0
BVpS4.31
TBVpS4.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.68%
ROE -83.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.68%
ROA(5y)-31.31%
ROE(3y)-49.49%
ROE(5y)-38.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 213.19%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.94
Quick Ratio 6.94
Altman-Z -2.13
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)165.62%
Cap/Depr(5y)149.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.79%
EPS Next Y-10.21%
EPS Next 2Y14.69%
EPS Next 3Y14.83%
EPS Next 5Y13.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year300%
Revenue Next 2Y350.89%
Revenue Next 3Y232.68%
Revenue Next 5Y136.6%
EBIT growth 1Y-24.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-57.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.72%
OCF growth 3YN/A
OCF growth 5YN/A